Literature DB >> 22100213

A randomized, double-blind trial comparing continuous thoracic epidural bupivacaine with and without opioid in contrast to a continuous paravertebral infusion of bupivacaine for post-thoracotomy pain.

Jay S Grider1, Timothy W Mullet, Sibu P Saha, Michael E Harned, Paul A Sloan.   

Abstract

OBJECTIVE: To compare the results of continuous epidural bupivacaine analgesia with and without hydromorphone to continuous paravertebral analgesia with bupivcaine in patients with post-thoracotomy pain.
DESIGN: A prospective, randomized, double-blinded trial.
SETTING: A teaching hospital. PARTICIPANTS: Patients at a tertiary care teaching hospital undergoing throracotomy for lung cancer.
INTERVENTIONS: Subjects were assigned randomly to receive a continuous thoracic epidural or paravertebral infusion. Patients in the epidural group were randomized to receive either bupivacaine alone or in combination with hydromorphone. Visual analog scores as well as incentive spirometery results were obtained before and after thoracotomy. METHODS AND MAIN
RESULTS: Seventy-five consecutive patients presenting for thoracotomy were enrolled in this institutional review board-approved study. On the morning of surgery, subjects were randomized to either an epidural group receiving bupvicaine with and without hydromorphone or a paravertebral catheter-infused bupvicaine. Postoperative visual analog scores and incentive spirometry data were measured in the postanesthesia care unit, the evening of the first operative day, and daily thereafter until postoperative day 4. Analgesia on all postoperative days was superior in the thoracic epidural group receiving bupivacaine plus hydromorphone. Analgesia was similar in the epidural and continuous paravertebral groups receiving bupivacaine alone. No significant improvement was noted by combining the continuous infusion of bupivacaine via the paravertebral and epidural routes. Incentive spirometry goals were best achieved in the epidural bupivacaine and hydromorphone group and equal in the group receiving bupivacaine alone either via epidural or continuous paravertebral infusion.
CONCLUSIONS: The current study provided data that fill gaps in the current literature in 3 important areas. First, this study found that thoracic epidural analgesia (TEA) with bupivacaine and a hydrophilic opioid, hydromorphone, may provide enhanced analgesia over TEA or continuous paravertebral infusion (CPI) with bupivacaine alone. Second, in the bupivacaine-alone group, the increased basal rates required to achieve analgesia resulted in hypotension more frequently than in the bupivacaine/hydromorphone combination group, underscoring the benefit of the synergistic activity. Finally, in agreement with previous retrospective studies, the current data suggest that CPI of local anesthetic appears to provide acceptable analgesia for post-thoracotomy pain.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22100213     DOI: 10.1053/j.jvca.2011.09.003

Source DB:  PubMed          Journal:  J Cardiothorac Vasc Anesth        ISSN: 1053-0770            Impact factor:   2.628


  10 in total

1.  Analgesic efficacy of two interscalene blocks and one cervical epidural block in arthroscopic rotator cuff repair.

Authors:  Jae-Yoon Kim; Kwang-Sup Song; Won-Joong Kim; Yong-Hee Park; Hyun Kang; Young-Cheol Woo; Hwa-Yong Shin
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2015-06-11       Impact factor: 4.342

Review 2.  Optimizing health before elective thoracic surgery: systematic review of modifiable risk factors and opportunities for health services research.

Authors:  Sean M Stokes; Elliot Wakeam; Mara B Antonoff; Leah M Backhus; Robert A Meguid; David Odell; Thomas K Varghese
Journal:  J Thorac Dis       Date:  2019-03       Impact factor: 2.895

3.  Comparison between continuous thoracic epidural block and continuous thoracic paravertebral block in the management of thoracic trauma.

Authors:  Shalendra Singh; Mathews Jacob; S Hasnain; Mathangi Krishnakumar
Journal:  Med J Armed Forces India       Date:  2016-12-24

Review 4.  Paravertebral block versus thoracic epidural for patients undergoing thoracotomy.

Authors:  Joyce H Y Yeung; Simon Gates; Babu V Naidu; Matthew J A Wilson; Fang Gao Smith
Journal:  Cochrane Database Syst Rev       Date:  2016-02-21

5.  Anesthesia for thoracic surgery: a survey of middle eastern practice.

Authors:  Abdelazeem Eldawlatly; Ahmed Turkistani; Ben Shelley; Mohamed El-Tahan; Alistair Macfie; John Kinsella
Journal:  Saudi J Anaesth       Date:  2012-07

Review 6.  A comparison of the analgesia efficacy and side effects of paravertebral compared with epidural blockade for thoracotomy: an updated meta-analysis.

Authors:  Xibing Ding; Shuqing Jin; Xiaoyin Niu; Hao Ren; Shukun Fu; Quan Li
Journal:  PLoS One       Date:  2014-05-05       Impact factor: 3.240

7.  Influence of Regional Anesthesia on the Rate of Chronic Postthoracotomy Pain Syndrome in Lung Cancer Patients.

Authors:  Victoria Khoronenko; Danil Baskakov; Marc Leone; Anna Malanova; Andrey Ryabov; Oleg Pikin; Maksim Golovashchenko
Journal:  Ann Thorac Cardiovasc Surg       Date:  2018-06-20       Impact factor: 1.520

8.  Efficacy and safety of general anesthesia combined with paravertebral blockade on postoperative recovery in patients undergoing pulmonary surgery: a systematic review and meta-analysis.

Authors:  Pusheng Ren; Yu Du; Guangquan He; Dan Jiang
Journal:  J Thorac Dis       Date:  2022-02       Impact factor: 2.895

Review 9.  Thoracic epidural analgesia: a new approach for the treatment of acute pancreatitis?

Authors:  Olivier Windisch; Claudia-Paula Heidegger; Raphaël Giraud; Philippe Morel; Léo Bühler
Journal:  Crit Care       Date:  2016-05-04       Impact factor: 9.097

10.  Increased Risk of Postthoracotomy Pain Syndrome in Patients with Prolonged Hospitalization and Increased Postoperative Opioid Use.

Authors:  Michelle A O Kinney; Adam K Jacob; Melissa A Passe; Carlos B Mantilla
Journal:  Pain Res Treat       Date:  2016-06-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.